Is gabapentin used to treat choroidal neovascular membrane (CNVM)?

Gabapentin is NOT used to treat CNVM

Gabapentin has no role in the treatment of choroidal neovascular membrane (CNVM). The FDA-approved indications for gabapentin are limited to postherpetic neuralgia and adjunctive therapy for partial seizures 1. There is no evidence—guideline-based, regulatory, or research-derived—supporting its use for CNVM.

Standard Treatment for CNVM

The established treatment for CNVM depends on the underlying etiology but centers on anti-VEGF therapy as the primary intervention:

First-Line Treatment

• Intravitreal anti-VEGF agents (aflibercept, bevacizumab, ranibizumab, or brolucizumab) are the standard of care 2
• Initial treatment typically involves injections at approximately 4-week intervals 2
• After three loading doses, maintenance regimens vary: monthly, treat-and-extend, or PRN (as-needed) protocols 2

Treatment Monitoring

• Optical coherence tomography (OCT) is the primary non-invasive tool for monitoring disease activity and treatment response 2
• Fluorescein angiography and OCT angiography (OCTA) are used when clinically indicated to detect active exudation or disease progression 2

Etiology-Specific Considerations

For inflammatory CNVM (as in Vogt-Koyanagi-Harada disease, punctate inner choroidopathy, or multifocal choroiditis):

• Combine anti-VEGF therapy with systemic anti-inflammatory/immunosuppressive treatment 3, 4, 5
• Options include oral, intravenous, or intravitreal corticosteroids; oral cyclosporine or methotrexate 4
• Control of underlying inflammation is essential for optimal outcomes 3, 4

For age-related macular degeneration (AMD)-associated CNVM:

• Anti-VEGF monotherapy is typically sufficient 2
• Photodynamic therapy (PDT) is a historical alternative but rarely used now 2

Common Pitfalls

• Do not confuse neuropathic pain medications with ophthalmic treatments: Gabapentin is an anticonvulsant/neuropathic pain agent with no mechanism of action relevant to neovascularization
• Do not delay anti-VEGF therapy: CNVM requires prompt treatment to prevent irreversible vision loss, particularly when subfoveal 6, 4
• Do not overlook underlying inflammation: In young patients or those with inflammatory etiologies, anti-VEGF alone may be insufficient—systemic immunosuppression is often necessary 4, 5

Visual Outcomes

With appropriate anti-VEGF treatment:

• Mean visual acuity gains of approximately 15 ETDRS letters are achievable 4
• 65-80% of patients show improved or stable visual outcomes 4
• Pediatric patients typically require fewer injections (average 2.3 per eye) compared to adults 6